| Literature DB >> 35754722 |
Erin N S McGowan1, Osanna Wong2, Eleanor Jones2,3, Julie Nguyen2,4, Janet Wee2,4, Maria C Demaria2, Devy Deliyanti5, Chad J Johnson6, Michael J Hickey4, Malcolm J McConville1, Jennifer L Wilkinson-Berka5, Mark D Wright2, Katrina J Binger1,2,7.
Abstract
Phagocytes migrate into tissues to combat infection and maintain tissue homeostasis. As dysregulated phagocyte migration and function can lead to inflammation or susceptibility to infection, identifying molecules that control these processes is critical. Here, we show that the tetraspanin CD82 restrains the migration of neutrophils and macrophages into tissues. Cd82 -/- phagocytes exhibited excessive migration during in vivo models of peritoneal inflammation, superfusion of CXCL1, retinopathy of prematurity, and infection with the protozoan parasite L. mexicana. However, with the latter, while Cd82 -/- macrophages infiltrated infection sites at higher proportions, cutaneous L. mexicana lesions were larger and persisted, indicating a failure to control infection. Analyses of in vitro bone-marrow-derived macrophages showed CD82 deficiency altered cellular morphology, and impaired gene expression and metabolism in response to anti-inflammatory activation. Altogether, this work reveals an important role for CD82 in restraining phagocyte infiltration and mediating their differentiation in response to stimulatory cues.Entities:
Keywords: Biological sciences; Immune system; Immunology
Year: 2022 PMID: 35754722 PMCID: PMC9213772 DOI: 10.1016/j.isci.2022.104520
Source DB: PubMed Journal: iScience ISSN: 2589-0042
Figure 1CD82 restrains phagocyte recruitment
(A and B) Wild-type (WT) and Cd82 mice were injected intraperitoneally with thioglycollate and (A) neutrophil and (B) macrophage infiltration into the peritoneal cavity was quantified by flow cytometry. Each data point represents a single mouse. Gating strategy is shown in Figure S1.
(C–F) Intravital microscopy was performed on the cremasteric microvasculature during 60 min superfusion with CXCL1. Parameters measured were (C) leukocyte rolling velocity, (D) rolling flux, (E) adhesion within the vasculature, and (F) emigration, each assessed prior to (0 min) and 30 and 60 min after commencing CXCL1 superfusion. Each data point represents a single mouse.
(G) Neutrophil migration in vitro was measured by transwell assays. Neutrophils were enriched from WT and Cd82 bone marrow by application to discontinuous Percoll gradients. Cells were then plated into the upper chamber of a transwell assay system. The number of cells which migrated into lower chambers containing either media (unstimulated), CXCL1, or LTB4 was quantified by flow cytometry. Each dot represents the mean from four independent experiments. All data are presented as mean ± SEM. p values for the effect of CD82 deficiency and the interaction of time were calculated by 2-way ANOVA and is indicated in the top left corner of each graph. Additionally, Sidak post-hoc multiple comparison analysis of individual time points is indicated by ∗p < 0.05; ∗∗p < 0.01; ∗∗∗p < 0.001. See also Figure S1.
Figure 2Cd82 mice have increased retinal macrophage recruitment and exacerbated pathology
(A) Representative whole mounts of retina from WT and Cd82 mice subjected to oxygen-induced retinopathy (OIR) and room-air (RA) controls. Vasculature was identified by immunolabeling with antibodies against lectin (green). Neovascular tufts (arrows) and avascularization (asterisk) are identified. Scale bar 250 μm.
(B) The proportion of neovascular tufts per retinal wholemount area was quantified. Neovascular tufts were not detected in control retina. Each data point represents a single mouse.
(C) Albumin per mg of retinal tissue of WT and Cd82 mice with OIR. Each data point represents a single mouse.
(D–F) Microglia/macrophage numbers in the retina were measured by immunolabeling for Iba1. (D) Retinal paraffin sections (3 μm) were immunolabeled with Iba1 (brown) and counterstained with hemotoxylin (blue). Neovascular tufts (arrows) and Iba1-positive cells (asterisk) are identified. Scale bar = 60 μm. (E) Quantification of Iba1 immunolabeling in paraffin sections from D. Each data point represents a single mouse. (F) Retinal wholemounts from A were immunolabeled for Iba1 (orange-yellow) and lectin (green). Scale bar = 100 μm.
(G–I) Whole retinas from WT and Cd82 mice with OIR were enzymatically digested into single-cell suspensions for flow cytometry. The number of macrophages, monocytes, and microglia was identified by their varying expression of CD45, CD11b, and Ly6C as indicated. Gating strategy is shown in Figure S2. Each data point represents a single mouse. All data are presented as mean ± SEM. Significance was measured by t-test (B, F–H) or 2-way ANOVA (E) where for the latter, the calculated p value for CD82 deficiency and the interaction of OIR is indicated in the top left corner and Sidak post-hoc multiple comparison analysis of individual time points. In all graphs, significance is ∗p < 0.05; ∗∗p < 0.01; ∗∗∗p < 0.001. See also Figure S2.
Figure 3Infection with L. mexicana is worsened in Cd82 mice
(A–D) WT and Cd82 mice were infected intradermally with the obligate intracellular parasite Leishmania (L) mexicana. (A) Scheme for the intradermal (ear) infection of WT and Cd82 mice with L. mexicana. Cutaneous lesion development was measured for a total of 12 weeks post infection. At 6 weeks, mice were sacrificed and the immune composition of lesions and draining lymph nodes (DLN) was measured by flow cytometry. (B) Cutaneous lesion sizes post infection with L. mexicana. Data from N = 10–13 mice pooled from two independent experiments. Shading indicates ±SEM (C) Cutaneous lesions sizes from B only at 6 weeks. Note that several WT mice had no lesions at this time point, indicated as 0 mm. Each data point represents a single mouse. (D) Cutaneous lesions and DLNs were enzymatically digested and analyzed by flow cytometry. The proportion of macrophages, monocytes, dendritic cells (DCs), and T cells was determined by staining with fluorescently conjugated antibodies. Y axes indicate how populations were determined. Cutaneous lesions are shown as proportion of CD11b+ cells while DLNs are shown as absolute numbers. Full gating strategy is shown in Figure S3.
(E and F) Macrophages were differentiated in vitro from the bone marrow of WT and Cd82 mice. After 7 days differentiation, macrophages were infected with L. mexicana-TurboRFP, parasite line expressing the fluorescent protein TurboRFP. The proportion of macrophages infected with L. mexicana-TurboRFP was measured 4 h (E) and 3 days (F) later by flow cytometry. Gating strategy to determine the proportion of viable, L. mexicana-TurboRFP-infected macrophages is shown in Figure S3. Parasitic burden is measured as the TurboRFP geometric mean fluorescence intensity (MFI) of infected macrophages. Parasitic index is calculated by the multiplication of the proportion infected and parasitic burden. Each dot represents the relative mean from four independent experiments, each with separate mice. All data are presented as mean ± SEM. Significance was measured by t-test (C–F) or 2-way ANOVA (B) with the overall significance indicated in the top left corner of the graph. For 2-way ANOVA, Sidak post-hoc multiple comparison analysis was performed of individual time points. In all graphs, significance is indicated by ∗p < 0.05; ∗∗p < 0.01; ∗∗∗p < 0.001. See also Figure S3.
Figure 4Activation to anti-inflammatory M2 phenotype is blunted in CD82-deficient macrophages
Macrophages were differentiated in vitro from the bone marrow of WT and Cd82 mice. After 7 days differentiation, macrophages were either left unstimulated (“Unstim.”) or activated to an anti-inflammatory “M2” phenotype with IL-4 and IL-13, or a pro-inflammatory “M1” phenotype with LPS and IFNγ, for a further 24 h.
(A) Macrophage morphology was measured by confocal fluorescence microscopy where rhodamine-phalloidin (gray) was used to stain actin filaments in WT and Cd82 macrophages activated in all conditions for 24 h. Nuclei were visualized with Hoeschst33342 (blue). Scale bars 20 μm. Dashed squares indicate insets shown in C.
(B) The circularity of WT and Cd82 macrophages was measured by the analysis of images from (A) with ImageJ. Each dot represents an individual cell from one representative experiment.
(C) Inset images of IL-4+IL-13-stimulated macrophages from (A).
(D) WT and Cd82 macrophages were activated as before and the surface expression of α5 (CD49e) and α4 (CD49d) was assessed by flow cytometry. Histograms of expression levels are shown with quantification of the geometric mean fluorescence intensity (bars).
(F–I) Anti-inflammatory macrophage activation after 24 h was measured by the mRNA expression of the signature genes arginase (Arg1; F) and mannose receptor (Mrc1; G), while pro-inflammatory macrophage activation was measured by the mRNA expression of nitric oxide synthase (Nos2; H) and tumor necrosis factor alpha (Tnfa; I).
(J–O) Mitochondrial metabolism of WT and Cd82 macrophages after activation for 24 h was measured by a Seahorse extracellular flux bioanalyser. (J and K) Representative oxygen consumption rate (OCR) profile over time of WT (J) and Cd82 (K) macrophages in response to sequential injections of oligomycin (“O”), FCCP (“F”) and antimycin A plus rotenone (“A + R”). (L) Basal energy (OCR versus ECAR) profile of WT and Cd82 macrophages. (M) Basal OCR of WT and Cd82 macrophages was calculated from profiles in J and K. WT macrophages showed typical responses where anti-inflammatory (IL-4 + IL-13) activation resulted in elevated OCR while pro-inflammatory (LPS + IFNγ) activation had decreased OCR. M2 Cd82 macrophages show blunted basal OCR. (N) Basal ECAR is a measure of cellular glycolytic metabolism. WT and Cd82 macrophages both exhibited similar increase in glycolysis. By contrast, Cd82 M2 macrophages again showed blunted basal ECAR. (O) The spare respiratory capacity (SRC) of WT and Cd82 macrophages was calculated from profiles in J and K. For all experiments (A–O), each dot represents technical replicates which were repeated in two independent experiments, where BMDMs were differentiated from separate mice. All data are presented as mean ± SEM. p values for the effect of CD82 deficiency and interaction with macrophage activation were calculated by 2-way ANOVA and is indicated in the top left corner of each graph. Additionally, Sidak post-hoc multiple comparison analysis of individual time points is indicated by ∗p < 0.05; ∗∗p < 0.01; ∗∗∗p < 0.001; ∗∗∗∗p < 0.0001. See also Figure S4.
| REAGENT or RESOURCE | SOURCE | IDENTIFIER |
|---|---|---|
| Anti-mouse CD11b-FITC (M1/70) | In-house | |
| Anti-mouse CD11b-AF700 (M1/70) | BD Biosciences | Cat# 557960, RRID: |
| Anti-mouse CD11b-APC (M1/70) | BioLegend | Cat# 10128 |
| Anti-mouse CD11b-PE-e610 | eBioscience | Cat# 61-0112-82, RRID: |
| Anti-mouse CD11c-PE-Cy7 (HL3) | BD Biosciences | Cat# 558079, RRID: |
| Anti-mouse CD16/32 | eBioscience | Cat# 14-0161-86, RRID: |
| Anti-mouse CD19-FITC (1D3) | BD Biosciences | Cat# 561740, RRID: |
| Anti-mouse CD45-APC-e780 (30-F11) | eBioscience | Cat# 47-0454-82, RRID: |
| Anti-mouse CD45-e506 | eBioscience | Cat# 69-0454-82, RRID: |
| Anti-mouse CD64-PerCP-e710 | eBioscience | Cat# 46-0641-82, RRID: |
| Anti-mouse F4/80-PE (CI:A3-1) | Cedarlane labs | Cat# CL8940PE, RRID: |
| Anti-mouse F4/80-A647 (T45-2342) | BD Biosciences | Cat# 565853, RRID: |
| Anti-mouse Gr1-PE (RB6-8C5) | BD Biosciences | Cat# 553128, RRID: |
| Anti-mouse Ly6C-Biotin (AL-21) | BD Biosciences | Cat# 557359, RRID: |
| Anti-mouse Ly6C-BV605 (AL-21) | BD Biosciences | Cat# 563011, RRID: |
| Anti-mouse Ly6G-AF700 (1A8) | BD Biosciences | Cat# 561236, RRID: |
| Anti-mouse Ly6G-PE (1A8) | BD Biosciences | Cat# 551461, RRID: |
| Anti-mouse Ly6G-APC (1A8) | BD Biosciences | Cat# 560599, RRID: |
| Anti-mouse MHCII-BV786 (M5/114.15) | BD Biosciences | Cat# 742894, RRID: |
| Anti-mouse TCRβ-e450 (H57-597) | eBioscience | Cat# 48-5961-82, RRID: |
| Anti-mouse Iba-1 | Wako, Japan | N/A |
| Goat anti-rabbit IgG H&L-AF568 | Life Technologies | N/A |
| Anti-rabbit IgG-biotin | Dako Cytomation | N/A |
| Sodium pentobarbitone | Virbac, Peakhurst, Australia | N/A |
| Liquid DAB+ Substrate Chromagen System | Dako | K3468 |
| Collagenase from clostridium histolyticum | Sigma Aldrich | C5138 |
| Deoxyribonuclease I | Sigma Aldrich | DN25 |
| LIVE/DEAD Fixable Aqua | Invitrogen | L34957 |
| Fixable Viability eFluor 780 | eBioscience | 65-0865-14 |
| Sodium thioglycollate | Sigma Aldrich | T0632 |
| FITC-isolectin B4 (from | Sigma Aldrich | L2895 |
| Hoescht33342 | ThermoFisher | H1399 |
| Alexa 488-Phalloidin | Invitrogen | A12379 |
| DePeX mounting medium | VWR International Ltd., Poole, England | SERA18243.01 |
| Mouse recombinant KC (CXCL1) | Peprotech | 250-11 |
| Mouse recombinant CSF-1 | Peprotech | 315-02 |
| Mouse recombinant IL-4 | eBiosciences | 14-8041-80 |
| Mouse recombinant IL-13 | eBiosciences | 14-8131-80 |
| Mouse recombinant IFN-γ | eBiosciences | 14-8311-63 |
| LPS-EB Ultrapure | Invivogen | Tlrl-3pelps |
| Vectastain ABC kit, standard | Vector Laboratories | PK-4000 |
| Mouse albumin ELISA kit | Bethyl Laboratories, Mongomery, TX, USA | E99-134 |
| WT C57Bl/6 | In-house breeding, Animal Research Laboratories, Clayton, Australia | N/A |
| In-house breeding, Animal Research Laboratories, Clayton, Australia | N/A | |
| In-house propagation | N/A | |
| In-house propagation | N/A | |
| Arginase 1 ( | Bioneer Pacific | N/A |
| Arginase 1 ( | Bioneer Pacific | N/A |
| Arginase 1 ( | Bioneer Pacific | N/A |
| Mannose receptor ( | Bioneer Pacific | N/A |
| Mannose receptor ( | Bioneer Pacific | N/A |
| Mannose receptor ( | Bioneer Pacific | N/A |
| Nitric oxide synthase ( | Bioneer Pacific | N/A |
| Nitric oxide synthase ( | Bioneer Pacific | N/A |
| Nitric oxide synthase ( | Bioneer Pacific | N/A |
| FlowJo | TreeStar Inc, OR, USA | N/A |
| GraphPad Prism (version 6) | San Diego, CA USA | N/A |
| ImageJ | NIH, MA, USA | N/A |
| PROOX 110 gas regulator | Reming Bioinstruments Co., Redfield NY USA | N/A |
| Nikon A1 laser scanning confocal microscope | Nikon Instruments Inc, Melville, NY, USA | N/A |
| Leica SP8 inverted confocal microscope | Leica Microsystems Pty Ltd, NSW, Australia | N/A |
| ZEISS LSM980 Axioplan 2 microscope | ZEISS Australia, North Ryde, NSW | N/A |
| LSR II Fortessa cell analyser | BD Biosciences Australia | N/A |
| Transwells 65 mm diameter 5.0 μm pore size | DKSH | 3421 |
| Caliper Vernier, Digital LCD | Westlab Pty Ltd | 080322-0003 |